Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

BIOM30001 - Frontiers in Biomedicine > Lecture 28 - Neuropathic Pain I > Flashcards

Lecture 28 - Neuropathic Pain I Flashcards

1
Q

How prevalent is neuropathic pain?

A

Around 20% of Australians suffer from it

In 5%, the pai has signficiant impact on ability to function and quality of life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List some 2° physical consequences of chronic pain

A
  • Deconditioning & postural changes
  • Changes to:
    • Psyche
    • Sleep patterns
    • Behaviour
    • Appetite
    • Thought
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the definition of chronic pain?

A

Persists for more than 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Outline the three broad groups of chronic pain

A
  1. Defined nociceptive basis
    • ​eg Chronic arthritis
  2. Well-defined neuropathological basis
    • ​eg Post-herpetic neuralgia
    • Peripheral neuropathy
  3. Idiopathic
    • ​Pathogenesis not well accepted
    • eg Chronic muskuloskeletal pain, esp. spinal pain
    • Some headaches
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

List the classification groups of pain

Give examples of each

A

A. Nociceptive

  1. Superficial somatic
    • ​Malignant ulcers
  2. Deep somatic
    • ​Bone metastases
    • Liver capsule distension or inflammation
  3. Visceral
    • Deep abdominal/chest masses​​​

B. Neuropathic

  • Trivial injury to the CNS or PNS
  • Tumour related:
    • Spinal cord compression
  • Non-tumour related:
    • Post-herpetic neuralgia
    • Phantom pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Outline the origin of stimulus for the various classifications of pain

A

A. Nociceptive

  1. Superficial somatic
    • ​Skin
    • Subcutaneous tissue
    • eg mucosa of mouth
  2. Deep somatic
    • ​Muscles
    • Bones
    • Joints
    • Organ capsules
    • Pleura
  3. Visceral
    • ​Solid or hollow organs
    • Deep tumour masses

B. Neuropathic

  • Damage to nocicpetive pathways
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the sensation of the various classifications of pain

A

A. Nociceptive

  • Superficial somatic
    • Hot, burning, stinging
  • Deep somatic
    • Dull aching
  • Visceral
    • Dull deep

B. Neuropathic

  • ‘Pins and needles’
  • Tingling & burning
  • Allodynia
  • Phantom pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

List things that can initiate neuropathic pain

A

Trivial injury to the PNS or CNS:

  • Infection
  • Trauma
  • Surgical intervention
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the persistence of neuropathic pain

A
  • Persists after the initial triggering stimulus has been removed
  • Lasts indefinitely
  • May escalate over time
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the effect of analgesics in neuropathic pain

A

Poor response to conventional analgesics (<50%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

List conditions which often lead to neuropathic pain

A
  • Diabetes: **Diabetic neuropathy **(20-25%)
  • Herpes zoster infection: Post-herpetic neuralgia (25-50%)
  • Post-masectomy pain (20%)
  • Cancer patients: neuropathic pain (33%)
    • +/- nociceptive pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List the various characteristics of neuropathic pain

A
  1. Spontaneous pain
    • ​​Shooting, burning, electric shock-like
  2. Hypersensitivity / hyperalgesia
    • ​​Increased pain derived from minimally painful stimuli
  3. Allodynia
    • ​​Pain experienced due to usually innocuous stimuli
      • Tactile
      • Thermal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What can we learn from studying pain in humans?

A

Mostly characterise pain states

Very few studies directly test mechanisms of pain (anatomical, biochemical, physiological)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Outline the value of animal models in pain research

A
  • Animal models were used in 1/3rd of articles in Pain
  • Allow investigation of:
    • Neurochemistry and anatomy
    • Samples from pain relevant tissues
      • eg mRNA
    • Pain conditions
    • Genetic and environmental conditions
    • Physiological mechanisms
  • Comparative value
    • Molecule / pain related phenomenon in man always found in rodents
  • Failures:
    • However, there are notable cases where antagonists/drugs developed in murine models have failed to translate into humans (ie not worked in humans)
  • Successes
    • Ziconitide
    • First found to be efficacious in mice
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the tail flick test

A
  • Application of heat stimulus to tail
  • Time recorded until spontaneous ‘flick’ withdrawal
    • A spinal reflex
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the animal model of neuropathic pain

A
  • Tight ligation of spinal nerves L5 and L6 on LHS
    • Supply Sciatic nerve
    • However, sciatic nerve is not completely ligated, the rat can still ambulate as normal.
  • Neuropathic signs within days:
    • Themal & tactile allodynia
  • Persists for at least five weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe the von Frey test

What is being tested?

Outline the process

A

Assesses tactile allodynia by measuring plantar withdrawal thresholds in respond to light touch

Process:

  • Graded force applied to plantar surface
  • Von Frey hairs applied sequentially
    • Calibrated nylon filaments
18
Q

Describe how the effect of neuropathy surgery can be measured

A

Von Frey testing

  • Unoperated side:
    • No tactile allodynia
    • No change in hindpaw tactile withdraw threshold
  • Operated side:
    • Tactile allodynia:
    • Decreased threshold
19
Q

Describe the structure of voltage-gated Ca2+ channels

A

Four subunits:

  • α1
    • Four homologous units
    • Transmembrane
    • Forms the pore
    • 10 different genes encoding this subunit have been identfied
  • β
    • Intracellular
    • Alpha helices
  • γ
    • Four transmembrane segments
    • Alpha helices
  • δ
    • One transmembrane segment
    • Attaches to extracellular α2 with a disulphide bond
  • α2
    • Binds δ extracellularly with disulfide bond
    • Contains α2δ ligand binding site
      • Binding site for pregabalin
20
Q

Describe the diversity of α1 subunits in voltage-gated Ca2+ channels

What is the implication of this?

A
  • 10 different genes encoding α1 subunits
    • L-type
      • Cav1.1-1.4
    • P/Q-type
      • Cav2.1
    • N-type
      • Cav2.2
    • R-type
      • Cav2.3
    • T-type
      • Cav3.1-3.3

​​

Different antagonists act on each of the subunit types

21
Q

What is the 1st line therapy for neuropathic pain?

Why?

A

Pregabalin (& gabapentin)

  • Both Gabapentinoids

Why:

  • Consistent efficacy
  • Few AEs
  • No drug-drug interactions
  • Safe

Efficacy demonstrated in:

  • Diabetic neuropathy
  • Post-herptic neuralgia
  • MS pain
  • Cancer pain
  • Phantom limb pain
  • Spinal cord injury
22
Q

What do gabapentin and pregabalin act on?

A

α2δ subunit ligand binding site

23
Q

What is the function of α2δ?

A
  • Accessory subunit of voltage-gated Ca channel
  • Modifies channel functional properties
    • ↑ time to activation
    • Thus ↑ Ca2+ current
24
Q

What is the role of α2δ in neuropathic pain?

A

Subunits are upregulated in the dorsal root ganglion and central terminals

​⇒ increased Ca2+ current

⇒ hyperexcited neuron

⇒ increased neurotransmitter release

⇒ increased nociception

25
Q

What is a hyperexcited neuron?

A
  • Increased expression of α2δ subunits
  • Increased time to inactivation of Cav channels
  • Increased Ca2+ current (influx)
  • More Ca2+ in synaptic terminals
  • Enhanced neurotransmitter release
26
Q

What are Gabapentinoids?

A
  • Anti-epileptic drugs
  • Shown to be effective in management of neuropathic pain
  • Examples
    • Gabapentin
    • Pregabalin
  • MOA:
    • Bind with high affinity to α2δ ligand binding site
    • Designed to mimic GABA
      • However:
        • Don’t interact with GABA-A/B receptors
        • Not metabolised into GABA
        • Don’t block GABA reuptake of metabolism
27
Q

Describe the features of pregabalin

  • Pharmacokinetics
  • Administration
A
  • Amino acid
  • Readily crosses the BBB
  • Non-saturable absorption
  • 90% bioavailability
  • Fast onset of action
  • Well tolerated
    • Few AEs
      • Somnolence
      • Ataxia
      • Weight gain
      • Dizziness
    • Few drug interactions
      • No liver metabolism
  • Twice daily administration
28
Q

How is pregabalin characterised?

Why?

A

‘Ca2+ channel modulator’

Down-regulates Cav channel activity, but the channel remains in the open state

29
Q

Describe the MOA of pregabalin

A
  1. Binds α2δ binding site
  2. ↓ Ca2+ influx through Cav channels into presynaptic neuron terminals
  3. ↓ release of excitatory neurotransmitters
    • Glutamate
    • Noradrenaline
    • Substance P
  4. ↓ excitation of post-synaptic neurons
  5. Analgesia
30
Q

Where in the body do gabapentinoids act?

A

Action is largely confined to the CNS

  • Dorsal root ganglia
  • Dorsal horn

This is because the N-type Cav are only really found in the CNS (not so much the PNS)

(Gabapentinoids only act on N-type Ca<span>v</span> channels)

31
Q

What does Ziconotide act on?

A

α1 subunit of N**-type **Cav channels (Cav2.2)

32
Q

What are conopeptides?

A

Peptides derived from various species of snails of genus Conus

Function in snail:

  • Venom synthesised by snail
  • Venom injected into prey by proboscis

Examples:

  • Conantokins: NMDA receptor blockers
  • ω-conotoxins: N-type Ca2+ channels blockers
  • μ-conotoxins: Na+ channels blockers
  • κ-conotoxins: K+ channels blockers
33
Q

Describe the features of Ziconotide

A
  • ω-conotoxin
  • From Conus magus
  • Folded polypeptide
  • 3 disulphide bonds
34
Q

Describe the importance of **N-type Cav **in nociception

A

Predominantly control neurotransmitter release from Aδ/C fibres in dorsal horn

  • N-type Cav allows Ca2+ influx into presynaptic terminals
  • Triggers neurotransmitter release (eg glutamate) into synaptic cleft

Thus, responsible for activation of nociception pathways in spinal cord

35
Q

Describe the MOA of Ziconotide

A
  1. Binds α1 subunit of N-type Cav
  2. Blocks Ca2+influx into presynaptic terminal of neuron
  3. Blocks release of excitatory neurotransmitters
  4. Secondary nociceptor neurons are not activated
  5. Nociceptive signals are not transmitted to the brain
  6. Analgesia
36
Q

Compare the efficacy of Ziconotide, Morphine and combination treatment of the two drugs

A

From most to least efficacious:

  • Combination treatment
  • Ziconotide
  • Morphine

Measured by Van Frey testing

Ziconotide is >10 times as potent as Morphine

(Additive analgesic effects observed when combined with morphine)

37
Q

Describe the clinical use of Ziconotide

A
  • Licensed as Prialt
  • Licensed for neuropathic and severe pain
  • Administered via intrathecal catheter
    • Under arachnoid membrane of the CNS
    • Mini-pump under the skin provides continuous dose
    • Major side effects if intravenous
  • Efficacy:
    • ​Analgesic efficacy for months
    • No evidence of tolerance or addiction
  • Use:
    • ​Individuals with conditions with associated refractory pain
      • AIDS
      • Cancer
    • Neuropathic pain
38
Q

Why is Prialt (Ziconotide) administered intrathecally?

A

Intravenous injection results in major cardiovascular AEs:

  • Bradycardia
  • Orthostatic hypotension
  • Massive drop in MAP

Peripheral administration:

  • Hypotension
  • Affects vagal and sympathic components of the baroreflex

This is not seen with intrathecal catheter administration

39
Q

What are the adverse effects of Ziconotide?

A

Only seen with high dose intrathecal administration (as well as i.v. and peripheral administration)

CNS side effects:

  • Dizziness
  • Nausea
  • Ataxia
  • Confusion
  • Memory impairment
  • Somnolence

When the dose is high, the drug gets into the brain.

  • Cardiovascular side effects:
    • ​Bradycardia
    • Orthostatic hypotension

This is because N-type Cav channels are found on cardiac cells and peripheral nerves (unlike gabapentin, which only binds channels in the CNS)

40
Q

What is CVID?

A
  • Another ω-conotoxin, N-type Cav channel blocker
  • From Conus catus
  • Currently under investigation as a therapeutic
  • More selective than Ziconotide
  • Fewer AEs
  • Can be administered intravenously
41
Q

What is different about **N-type Cav **in neuropathic pain states?

A
  • Upregulation of α2δ subunits
    • ​Increased conductance of channels
  • Upregulation of N-type channel in general
    • ​Increased nociceptive transmission in spinal cord
42
Q

Where does ziconotide come from?

A

Conopeptide from Conus magus

BIOM30001 - Frontiers in Biomedicine (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions